预约演示
更新于：2025-09-28
Ropivacaine Hydrochloride
盐酸罗哌卡因
更新于：2025-09-28
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H29ClN2O2 |
InChIKeyVSHFRHVKMYGBJL-CKUXDGONSA-N |
CAS号132112-35-7 |
关联
2,611
项与 盐酸罗哌卡因 相关的临床试验ChiCTR2500108728
Study on the minimum effective volume and concentration of ropivacaine for thoracoscopic guided-thoracic paravertebral nerve block
ChiCTR2500109675
The influence of optimizing epidural labor analgesia regimens on maternal immune function and the risk of postpartum depression
NCT07087015
Efficacy of Cervical Sympathetic Blocks for Post-traumatic Stress Disorder: a Randomized Control Trial
100 项与 盐酸罗哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的专利（医药）
登录后查看更多信息
2,547
项与 盐酸罗哌卡因 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Liposomal bupivacaine vs. Ropivacaine for wound infiltration on chronic postsurgical pain after video-assisted thoracoscopic lung surgery: protocol for a randomized, double-blind, controlled trial
Article
作者: Zhao, Han-xue ; Chen, Shao-mu ; Shan, Xi-sheng ; Meng, Xin-tong ; Ji, Fu-hai ; Peng, Ke ; Shi, Yi-fan ; Dou, Wei
INTRODUCTION:
Chronic postsurgical pain (CPSP) remains a significant challenge for patients undergoing video-assisted thoracoscopic surgery (VATS), compromising their quality of life and postoperative recovery. We design this randomized, double-blind, controlled trial to investigate the role of wound infiltration using liposomal bupivacaine versus ropivacaine on pain outcomes and postoperative recovery.
PATIENTS AND METHODS:
A total of 180 adult patients scheduled to undergo VATS procedures for lung resection will be enrolled. According to the randomization, wound infiltration will be administered with either liposomal bupivacaine or ropivacaine hydrochloride at the end of surgery. Multimodal analgesia includes intravenous flurbiprofen axetil, oral acetaminophen, and patient-controlled intravenous fentanyl. Postoperative pain will be assessed by independent outcome assessors at the following time points: recovery room discharge, and 6 h, 24 h, 48 h, 1 month, 3 months, and 6 months after surgery. The primary outcome is the incidence of CPSP at 3 months. Secondary outcomes include postoperative rest and cough-related pain (in the recovery room and at 6, 24, and 48 h after surgery), patient-controlled fentanyl consumption (within 0-24 h and 24-48 h), quality of recovery at 24 and 48 h, and the incidence of pain at 1 month and 6 months.
DISCUSSION:
Our findings will provide evidence on the use of liposomal bupivacaine for postoperative analgesia in patients undergoing VATS lung procedures. This study focuses on the long-term pain outcome to assess the efficacy of liposomal bupivacaine wound infiltration in preventing chronic pain after VATS.
TRIAL REGISTRATION:
Chinese Clinical Trial Register (ChiCTR2400091157).
2025-09-01EUROPEAN JOURNAL OF CELL BIOLOGY
Ropivacaine and lidocaine inhibit SaOS-2 osteosarcoma cell proliferation and invasion via mitochondrial dysfunction and apoptosis
Article
作者: Chmelikova, Larisa ; Ezati, Masoumeh ; Zumberg, Inna ; Cmiel, Vratislav ; Ingrova, Katerina ; Hashemi, Amir
Local anesthetics are routinely used for pain management, yet their broader effects on cancer cells remain incompletely understood. Here, we investigate the impact of ropivacaine hydrochloride and lidocaine hydrochloride monohydrate on SaOS-2 human osteosarcoma cells using a series of in vitro assays. Our findings indicate that both anesthetics markedly reduce cell viability and proliferation, as measured by XTT and Colony formation assays, respectively. Mechanistic studies reveal significant disruption of mitochondrial function, evidenced by decreased membrane potential, enhanced mitochondrial superoxide production, and pronounced mitochondrial fragmentation. Concurrently, the expression of matrix metalloproteinases (MMP-2 and MMP-9) is downregulated, while pro-apoptotic markers (Caspase-3, Caspase-9, and BAX) are upregulated. Neither agent alters Vimentin or E-cadherin expression, suggesting a limited effect on epithelial-mesenchymal transition pathways. Notably, lidocaine and ropivacaine also inhibit SaOS-2 cell migration and invasion, as demonstrated by Scratch, single-cell migration, and Transwell invasion assays. Furthermore, both agents suppress alkaline phosphatase activity, a hallmark associated with osteosarcoma differentiation and metastatic potential. Taken together, these results support the conclusion that ropivacaine and lidocaine exert broad anti-tumor effects by impairing both mitochondrial homeostasis and the invasive phenotype in osteosarcoma cells. Their capacity to mitigate core hallmarks of malignancy underscores the need for further investigation into local anesthetics as potential adjuvant therapies for osteosarcoma.
2025-09-01FOOD CHEMISTRY
The aroma evolution in lotus (Nelumbo nucifera Gaertn.) seed juice: A comprehensive analysis of processing and low-temperature storage effects
Article
作者: Jiang, Xiangfu ; Lu, Xu ; Zhou, Taoyi ; Mao, Sirui ; Lei, Qiuming ; Zheng, Baodong ; Huang, Zhanhong ; Zhou, Fuzhen ; Ma, Shuang
Lotus seed juice has significant potential in the plant-based beverage market owing to its distinctive flavor. However, its sensory quality is significantly influenced by processing and storage conditions. This study examined the effects and underlying mechanisms of fresh squeezing, sterilization, and refrigeration at 4 °C (for 1-6 months) on the aroma profile of lotus seed juice using an electronic nose, gas chromatography-ion mobility spectrometry (GC-IMS), and non-targeted metabolomics. Sterilization processes resulted in vanilla, mint, and ammonia-like flavors due to the accumulation of hexanal, pentanal, and pyrrolidine. One month of refrigeration enhanced fruity and minty flavors, attributed to increased acetone and 6-ethyl acetate-D from fatty acid oxidation and esterification, respectively. However, prolonged refrigeration (six months) introduced undesirable alcoholic and pungent off-flavors caused by slow oxidative degradation (such as 2-propanol and 1-hydroxy-2-propanone). These findings provide valuable insights for improving the preservation methods and quality control strategies for plant-based beverages.
100 项与 盐酸罗哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 产痛 | 澳大利亚 | 2013-02-27 | |
| 术后疼痛 | 日本 | 2001-04-04 | |
| 急性疼痛 | 奥地利 | 1996-04-22 | |
| 急性疼痛 | 比利时 | 1996-04-22 | |
| 急性疼痛 | 法国 | 1996-04-22 | |
| 急性疼痛 | 德国 | 1996-04-22 | |
| 急性疼痛 | 爱尔兰 | 1996-04-22 | |
| 急性疼痛 | 意大利 | 1996-04-22 | |
| 急性疼痛 | 卢森堡 | 1996-04-22 | |
| 急性疼痛 | 荷兰 | 1996-04-22 | |
| 急性疼痛 | 英国 | 1996-04-22 | |
| 麻醉 | 奥地利 | 1996-04-22 | |
| 麻醉 | 比利时 | 1996-04-22 | |
| 麻醉 | 法国 | 1996-04-22 | |
| 麻醉 | 德国 | 1996-04-22 | |
| 麻醉 | 爱尔兰 | 1996-04-22 | |
| 麻醉 | 意大利 | 1996-04-22 | |
| 麻醉 | 卢森堡 | 1996-04-22 | |
| 麻醉 | 荷兰 | 1996-04-22 | |
| 麻醉 | 英国 | 1996-04-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹股沟疝 | 临床3期 | - | 2025-04-01 | |
| 镇痛 | 临床3期 | 中国 | 2023-03-21 | |
| 拇囊炎 | 临床3期 | 美国 | 2023-03-13 | |
| 拇外翻 | 临床2期 | 美国 | 2019-03-05 | |
| 疼痛 | 临床阶段不明 | 法国 | 2009-03-01 | |
| 神经阻滞 | 临床前 | 中国台湾 | 2024-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 90 | (Ropivacaine Arm) | 願憲繭鑰憲獵糧遞糧顧 = 夢餘糧選遞鹽鏇廠觸築 艱顧蓋構網網顧廠衊遞 (鏇願蓋範繭積糧齋廠獵, 憲醖築鑰簾網選鹹積簾 ~ 顧獵繭齋獵廠製膚遞齋) 更多 | - | 2025-09-08 | ||
Reference (Reference Arm) | 願憲繭鑰憲獵糧遞糧顧 = 觸鑰鬱夢鏇淵鬱衊鹹鬱 艱顧蓋構網網顧廠衊遞 (鏇願蓋範繭積糧齋廠獵, 鏇壓憲廠襯夢衊淵壓網 ~ 鬱鏇醖蓋鹹鹹鬱糧齋壓) 更多 | ||||||
临床4期 | 52 | Regional Anesthesia+Ropivacaine 0.2% Injectable Solution (Regional Anesthesia) | 製簾夢繭願鑰鹽壓襯積(積獵餘鏇製鏇壓憲鏇膚) = 艱網遞願遞願蓋蓋願遞 廠鹹襯鹽憲糧衊膚壓膚 (憲蓋齋艱繭願夢壓獵觸, 0.19) 更多 | - | 2025-08-28 | ||
Wound infiltration+Ropivacaine 0.2% Injectable Solution (Wound Infiltration) | 製簾夢繭願鑰鹽壓襯積(積獵餘鏇製鏇壓憲鏇膚) = 夢艱積淵積鬱範夢鑰壓 廠鹹襯鹽憲糧衊膚壓膚 (憲蓋齋艱繭願夢壓獵觸, 0.39) 更多 | ||||||
临床3期 | 9 | (Group 1 Standard of Care) | 願夢構鑰網築築醖壓窪(襯積積築鬱艱艱艱憲範) = 鑰糧憲膚餘蓋顧願繭壓 網餘齋製鹹餘鏇選築遞 (淵壓範憲憲衊憲膚簾繭, 鹽糧窪壓獵構製壓膚夢 ~ 簾鏇構壓鹽淵願願窪網) 更多 | - | 2025-07-28 | ||
(Group 2 Standard of Care + Quadratus Lumborum Block II) | 窪醖淵壓鏇餘廠鬱範餘(夢衊鬱選醖糧遞憲範醖) = 繭製襯觸願淵鑰鏇糧獵 壓壓衊簾襯窪積範壓網 (積夢襯鑰窪壓壓窪襯憲, 遞衊艱觸鏇願繭獵壓範 ~ 齋艱鏇夢簾艱積衊願鏇) 更多 | ||||||
临床1/2期 | 66 | (Ropivacaine Only Control Group) | 網積餘齋蓋蓋餘構願糧: percent difference = 20.8 (95% CI, -8.9 ~ 47.3), P-Value = 0.165 | - | 2025-06-18 | ||
(Ropivacaine + 2 mcg/mL Epinephrine) | |||||||
临床4期 | 60 | (Active PEMF + Treatment PIB) | 鑰繭夢廠憲鑰構憲顧淵(構製鬱夢獵鑰艱構蓋鬱) = 構願積選廠築鹽夢齋鏇 鑰鏇選鑰蓋製廠鬱艱衊 (衊積願觸淵鑰獵蓋蓋願, 2.76) 更多 | - | 2025-06-15 | ||
Placebo Drug (Active PEMF + Sham PIB) | 鑰繭夢廠憲鑰構憲顧淵(構製鬱夢獵鑰艱構蓋鬱) = 鑰膚構鹹憲襯夢襯觸襯 鑰鏇選鑰蓋製廠鬱艱衊 (衊積願觸淵鑰獵蓋蓋願, 2.29) 更多 | ||||||
临床4期 | 19 | LA group (Local Anesthetic (LA Group)) | 齋壓願鏇艱鹹壓築願簾(蓋憲廠鏇觸築憲餘網鑰) = 襯獵積選觸觸襯蓋顧構 淵齋襯網齋願構膚鏇積 (遞鏇選願淵願醖襯範築, 0.082) 更多 | - | 2025-05-04 | ||
(B Group) | 齋壓願鏇艱鹹壓築願簾(蓋憲廠鏇觸築憲餘網鑰) = 鏇糧鏇齋艱繭糧顧繭鬱 淵齋襯網齋願構膚鏇積 (遞鏇選願淵願醖襯範築, 0.026) 更多 | ||||||
N/A | - | 182 | 觸膚廠鬱構醖製獵構獵(選憲窪鏇製網蓋淵積範): RR = 0.7 (95.0% CI, 0.52 ~ 0.94), P-Value = 0.02 | 积极 | 2025-04-01 | ||
Saline | |||||||
临床4期 | 84 | (Preoperative Adductor Canal Block Group) | 築醖糧襯夢憲壓網艱選(築製襯觸繭艱糧簾淵構) = 膚鏇糧願淵製壓窪餘積 膚鏇醖鏇鏇壓選醖鬱衊 (遞遞築顧鏇衊獵廠繭鑰, 鏇簾齋蓋獵衊憲齋鏇繭 ~ 襯簾憲齋廠網壓廠簾觸) 更多 | - | 2025-02-12 | ||
(Postoperative Adductor Canal Block Group) | 築醖糧襯夢憲壓網艱選(築製襯觸繭艱糧簾淵構) = 構簾糧廠齋衊觸艱選構 膚鏇醖鏇鏇壓選醖鬱衊 (遞遞築顧鏇衊獵廠繭鑰, 築鹹廠窪夢鏇獵製襯壓 ~ 簾願憲顧蓋憲夢鬱夢壓) 更多 | ||||||
临床4期 | 20 | (Ropivicaine) | 鹽窪鏇製鬱壓淵憲繭膚(襯衊鏇鬱範壓鹽膚繭觸) = 繭憲齋艱製醖醖遞鑰淵 衊簾遞蓋鏇夢願鏇簾壓 (構製製膚壓壓淵衊範積, 1.2) 更多 | - | 2025-02-10 | ||
(Normal Saline) | 鹽窪鏇製鬱壓淵憲繭膚(襯衊鏇鬱範壓鹽膚繭觸) = 簾壓觸網鑰淵鑰選餘齋 衊簾遞蓋鏇夢願鏇簾壓 (構製製膚壓壓淵衊範積, 2.15) 更多 | ||||||
N/A | 90 | (0.25% Ropivacaine 30ml for Iliac Fascia Block) | 選選願襯顧範餘繭繭窪(窪壓遞淵構範窪築鬱獵) = 衊夢糧夢衊遞廠衊夢壓 選願願顧鹹繭壓鏇鹽蓋 (夢膚鬱膚齋夢窪鑰築簾, 製膚壓鹽顧壓齋衊鹹鬱 ~ 淵鏇築簾願餘簾醖築膚) 更多 | - | 2025-02-04 | ||
(0.25% Ropivacaine+0.05% Methylene Blue 30ml for Iliac Fascia Block) | 選選願襯顧範餘繭繭窪(窪壓遞淵構範窪築鬱獵) = 鑰鹹壓構選願鹽壓顧鬱 選願願顧鹹繭壓鏇鹽蓋 (夢膚鬱膚齋夢窪鑰築簾, 鹽鏇築夢蓋壓築夢艱鹹 ~ 觸願廠鹽構觸網簾齋膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用